{"organizations": [], "uuid": "4bf385e75281bee685dba51967401dd8bf1d71f2", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180305.html", "section_title": "Archive News &amp; Video for Monday, 05 Mar 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-prometic-receives-rare-pediatric-d/brief-prometic-receives-rare-pediatric-disease-designation-from-u-s-fda-for-its-inter-alpha-inhibitor-proteins-idUSFWN1QN0ER", "country": "US", "domain_rank": 408, "title": "BRIEF-Prometic Receives Rare Pediatric Disease Designation From U.S. FDA For Its Inter-Alpha-Inhibitor-Proteins", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.91, "site_type": "news", "published": "2018-03-05T20:16:00.000+02:00", "replies_count": 0, "uuid": "4bf385e75281bee685dba51967401dd8bf1d71f2"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-prometic-receives-rare-pediatric-d/brief-prometic-receives-rare-pediatric-disease-designation-from-u-s-fda-for-its-inter-alpha-inhibitor-proteins-idUSFWN1QN0ER", "ord_in_thread": 0, "title": "BRIEF-Prometic Receives Rare Pediatric Disease Designation From U.S. FDA For Its Inter-Alpha-Inhibitor-Proteins", "locations": [], "entities": {"persons": [], "locations": [{"name": "u.s.", "sentiment": "none"}], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "prometic life sciences inc", "sentiment": "negative"}, {"name": "fda", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "March 5 (Reuters) - Prometic Life Sciences Inc:\n* PROMETIC RECEIVES RARE PEDIATRIC DISEASE DESIGNATION FROM U.S. FDA FOR ITS INTER-ALPHA-INHIBITOR-PROTEINS\n* PROMETIC LIFE SCIENCES INC - IN ADDITION TO RARE PEDIATRIC DISEASE DESIGNATION, IAIP HAS ALSO BEEN GRANTED AN ORPHAN DRUG DESIGNATION BY FDA\n* PROMETIC LIFE SCIENCES - COSTS ASSOCIATED WITH CLINICAL PROGRAM RELATED TO THE PEDIATRIC & ORPHAN DRUG DESIGNATIONS â€œWILL NOT IMPACT OUR FY2018 Source text for Eikon: Further company coverage:\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-03-05T20:16:00.000+02:00", "crawled": "2018-03-06T22:15:03.001+02:00", "highlightTitle": ""}